Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 08-Mar-18 12:12 PM View:  | Denner Alexander J Director | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 5,001 | -- | -- | (< 1%) 1.17M to 1.17M | |
| 08-Mar-18 11:35 AM View: | Celona Lucia EVP, HR & Corp Commun. Officer | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 20,396 | -- | -- | (100%) 20.4K to 0 | |
| 08-Mar-18 12:49 PM View: | Posner Brian S Director | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 6,693 | -- | -- | (100%) 6.69K to 0 | |
| 08-Mar-18 12:22 PM View: | Duvall Diantha Chief Accounting Officer | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 2,791 | -- | -- | (100%) 2.79K to 0 | |
| 08-Mar-18 12:12 PM View: | Denner Alexander J Director | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 1,165,000 | -- | -- | (100%) 1.17M to 0 | |
| 08-Mar-18 12:44 PM View: | Paglia Louis J Director | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 3,056 | -- | -- | (100%) 3.06K to 0 | |
| 08-Mar-18 11:47 AM View: | Cox John Chief Executive Officer Director | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 185,094 | -- | -- | (100%) 185.09K to 0 | |
| 08-Mar-18 11:42 AM View: | Vivaldi Coelho Rogerio EVP, Chief Global Therapeutics | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 5,758 | -- | -- | (100%) 5.76K to 0 | |
| 08-Mar-18 12:31 PM View: | Greene John EVP, CFO and Treasurer | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 5,951 | -- | -- | (100%) 5.95K to 0 | |
| 08-Mar-18 12:53 PM View: | Protopapas Anna Director | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 1,056 | -- | -- | (100%) 1.06K to 0 | |
| 08-Mar-18 11:25 AM View: | Brudnick Richard EVP, Business Development | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 22,952 | -- | -- | (100%) 22.95K to 0 | |
| 08-Mar-18 12:36 PM View: | Harris Timothy J.R. EVP, R & D | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 839 | -- | -- | (100%) 0.84K to 0 | |
| 08-Mar-18 12:17 PM View: | Difabio Andrea EVP, Chief Legal Officer | Bioverativ Inc. (BIVV) | 08-Mar-18 | Disposition | 30,600 | -- | -- | (100%) 30.6K to 0 | |
| 08-Mar-18 12:44 PM View: | Paglia Louis J Director | Bioverativ Inc. (BIVV) | 05-Mar-18 | Gift | 2,000 | -- | -- | (40%) 5.06K to 3.06K | |
| 05-Mar-18 5:02 PM View: | Duvall Diantha Chief Accounting Officer | Bioverativ Inc. (BIVV) | 02-Mar-18 | Payment of Exercise | 105 | $104.73 | $10,996.70 | (4%) 2.9K to 2.79K | (< 1%) |
| 26-Feb-18 5:04 PM View: | Brudnick Richard EVP, Business Development | Bioverativ Inc. (BIVV) | 23-Feb-18 | Payment of Exercise | 924 | $104.74 | $96,779.80 | (4%) 23.88K to 22.95K | (< 1%) |
| 26-Feb-18 5:11 PM View: | Cox John Chief Executive Officer Director | Bioverativ Inc. (BIVV) | 23-Feb-18 | Payment of Exercise | 5,794 | $104.74 | $606,864.00 | (3%) 190.89K to 185.09K | (< 1%) |
| 26-Feb-18 5:07 PM View: | Difabio Andrea EVP, Chief Legal Officer | Bioverativ Inc. (BIVV) | 23-Feb-18 | Payment of Exercise | 917 | $104.74 | $96,046.60 | (3%) 31.33K to 30.41K | (< 1%) |
| 26-Feb-18 5:09 PM View: | Celona Lucia EVP, HR & Corp Commun. Officer | Bioverativ Inc. (BIVV) | 23-Feb-18 | Payment of Exercise | 389 | $104.74 | $40,743.90 | (2%) 20.41K to 20.02K | (< 1%) |
| 26-Feb-18 5:13 PM View: | Duvall Diantha Chief Accounting Officer | Bioverativ Inc. (BIVV) | 22-Feb-18 | Payment of Exercise | 168 | $104.30 | $17,522.40 | (5%) 3.06K to 2.9K | (< 1%) |
| 26-Feb-18 5:11 PM View: | Cox John Chief Executive Officer Director | Bioverativ Inc. (BIVV) | 22-Feb-18 | Payment of Exercise | 13,973 | $104.30 | $1,457,380.00 | (7%) 204.86K to 190.89K | (< 1%) |
| 26-Feb-18 5:07 PM View: | Difabio Andrea EVP, Chief Legal Officer | Bioverativ Inc. (BIVV) | 22-Feb-18 | Payment of Exercise | 2,011 | $104.30 | $209,747.00 | (6%) 33.34K to 31.33K | (< 1%) |
| 26-Feb-18 5:09 PM View: | Celona Lucia EVP, HR & Corp Commun. Officer | Bioverativ Inc. (BIVV) | 22-Feb-18 | Payment of Exercise | 1,235 | $104.30 | $128,810.00 | (6%) 21.64K to 20.41K | (< 1%) |
| 26-Feb-18 5:04 PM View: | Brudnick Richard EVP, Business Development | Bioverativ Inc. (BIVV) | 22-Feb-18 | Payment of Exercise | 1,419 | $104.30 | $148,002.00 | (6%) 25.3K to 23.88K | (< 1%) |
| 15-Feb-18 4:59 PM View: | Difabio Andrea EVP, Chief Legal Officer | Bioverativ Inc. (BIVV) | 14-Feb-18 | Payment of Exercise | 1,136 | $103.52 | $117,599.00 | (3%) 34.48K to 33.34K | (1%) |
| 15-Feb-18 4:59 PM View: | Difabio Andrea EVP, Chief Legal Officer | Bioverativ Inc. (BIVV) | 14-Feb-18 | Option Exercise | 3,744 | -- | -- | 12% 30.73K to 34.48K | |
| 15-Feb-18 5:02 PM View: | Celona Lucia EVP, HR & Corp Commun. Officer | Bioverativ Inc. (BIVV) | 14-Feb-18 | Payment of Exercise | 1,141 | $103.52 | $118,116.00 | (5%) 22.78K to 21.64K | (1%) |
| 15-Feb-18 5:02 PM View: | Celona Lucia EVP, HR & Corp Commun. Officer | Bioverativ Inc. (BIVV) | 14-Feb-18 | Option Exercise | 3,744 | -- | -- | 20% 19.04K to 22.78K | |
| 15-Feb-18 5:09 PM View: | Vivaldi Coelho Rogerio EVP, Chief Global Therapeutics | Bioverativ Inc. (BIVV) | 14-Feb-18 | Option Exercise | 7,114 | -- | -- | 2258% 0.32K to 7.43K | |
| 15-Feb-18 5:24 PM View: | Greene John EVP, CFO and Treasurer | Bioverativ Inc. (BIVV) | 14-Feb-18 | Option Exercise | 7,114 | -- | -- | 1423% 0.5K to 7.61K | |
| 15-Feb-18 5:04 PM View: | Cox John Chief Executive Officer Director | Bioverativ Inc. (BIVV) | 14-Feb-18 | Option Exercise | 24,339 | -- | -- | 13% 191.34K to 215.68K | |
| 15-Feb-18 5:06 PM View: | Brudnick Richard EVP, Business Development | Bioverativ Inc. (BIVV) | 14-Feb-18 | Payment of Exercise | 1,137 | $103.52 | $117,702.00 | (4%) 26.43K to 25.3K | (1%) |
| 15-Feb-18 5:06 PM View: | Brudnick Richard EVP, Business Development | Bioverativ Inc. (BIVV) | 14-Feb-18 | Option Exercise | 3,744 | -- | -- | 17% 22.69K to 26.43K | |
| 15-Feb-18 5:11 PM View: | Duvall Diantha Chief Accounting Officer | Bioverativ Inc. (BIVV) | 14-Feb-18 | Payment of Exercise | 454 | $103.52 | $46,998.10 | (13%) 3.52K to 3.06K | (1%) |
| 15-Feb-18 5:11 PM View: | Duvall Diantha Chief Accounting Officer | Bioverativ Inc. (BIVV) | 14-Feb-18 | Option Exercise | 1,390 | -- | -- | 65% 2.13K to 3.52K | |
| 15-Feb-18 5:09 PM View: | Vivaldi Coelho Rogerio EVP, Chief Global Therapeutics | Bioverativ Inc. (BIVV) | 14-Feb-18 | Payment of Exercise | 2,126 | $103.52 | $220,084.00 | (29%) 7.43K to 5.3K | (1%) |
| 15-Feb-18 5:04 PM View: | Cox John Chief Executive Officer Director | Bioverativ Inc. (BIVV) | 14-Feb-18 | Payment of Exercise | 10,819 | $103.52 | $1,119,980.00 | (5%) 215.68K to 204.86K | (1%) |
| 15-Feb-18 5:24 PM View: | Greene John EVP, CFO and Treasurer | Bioverativ Inc. (BIVV) | 14-Feb-18 | Payment of Exercise | 2,118 | $103.52 | $219,255.00 | (28%) 7.61K to 5.5K | (1%) |
| 13-Feb-18 5:01 PM View: | Cox John Chief Executive Officer Director | Bioverativ Inc. (BIVV) | 11-Feb-18 | Payment of Exercise | 7,672 | $103.05 | $790,600.00 | (4%) 199.01K to 191.34K | (2%) |
| 13-Feb-18 5:01 PM View: | Cox John Chief Executive Officer Director | Bioverativ Inc. (BIVV) | 11-Feb-18 | Option Exercise | 18,381 | $9.53 | $175,171.00 | 10% 180.63K to 199.01K | |
| 03-Nov-17 4:06 PM View: | Difabio Andrea EVP, Chief Legal Officer | Bioverativ Inc. (BIVV) | 02-Nov-17 | Payment of Exercise | 636 | $53.65 | $34,121.40 | (2%) 31.37K to 30.73K | (96%) |
| 03-Nov-17 4:11 PM View: | Celona Lucia EVP, HR & Corp Commun. Officer | Bioverativ Inc. (BIVV) | 02-Nov-17 | Payment of Exercise | 318 | $53.65 | $17,060.70 | (2%) 19.25K to 18.93K | (96%) |
| 31-Aug-17 9:47 PM View: | Denner Alexander J Director | Bioverativ Inc. (BIVV) | 31-Aug-17 | Grant | 932 | $56.69 | $52,835.10 | < 1% 1.17M to 1.17M | 85% |
| 10-Aug-17 4:50 PM View: | Posner Brian S Director | Bioverativ Inc. (BIVV) | 09-Aug-17 | Market Purchase | 1,000 | $59.19 | $59,189.90 | 18% 5.69K to 6.69K | 77% |
| 08-Aug-17 4:53 PM View: | Paglia Louis J Director | Bioverativ Inc. (BIVV) | 07-Aug-17 | Market Purchase | 2,000 | $59.70 | $119,400.00 | 65% 3.06K to 5.06K | 76% |
| 29-Jun-17 5:10 PM View: | Duvall Diantha Chief Accounting Officer | Bioverativ Inc. (BIVV) | 28-Jun-17 | Market Sale (Planned) | 818 | $60.47 | $49,464.50 | (28%) 2.95K to 2.13K | (74%) |
| 01-Jun-17 5:16 PM View: | Denner Alexander J Director | Bioverativ Inc. (BIVV) | 30-May-17 | Market Purchase | 90,000 | $55.93 | $5,033,480.00 | 8% 1.08M to 1.17M | 88% |
| 26-May-17 4:02 PM View: | Paglia Louis J Director | Bioverativ Inc. (BIVV) | 26-May-17 | Market Purchase | 2,000 | $57.76 | $115,520.00 | 189% 1.06K to 3.06K | 82% |
| 26-May-17 7:20 PM View: | Denner Alexander J Director | Bioverativ Inc. (BIVV) | 26-May-17 | Market Purchase | 450,000 | $57.21 | $25,745,100.00 | 26% 1.75M to 2.2M | 83% |
| 26-May-17 7:20 PM View: | Denner Alexander J Director | Bioverativ Inc. (BIVV) | 25-May-17 | Market Purchase | 130,000 | $54.98 | $7,147,910.00 | 8% 1.62M to 1.75M | 91% |
